论文部分内容阅读
目的:探讨儿童重症肺炎支原体肺炎的临床疗效,以提高临床诊断和治疗水平。方法:将77例患儿根据应用阿奇霉素和红霉素治疗分成阿奇霉素组(A组)和红霉素组(B组),观察其临床疗效。结果:两组患儿在性别、年龄、高热及肺内并发症方面均无统计学差异(P>0.05),有可比性;B组患儿的联合用抗生素时间明显短于A组,差异有统计学意义(P<0.05);而退热时间B组短于A组、肺部啰音减少天数A组短于B组、咳嗽好转天数方面均无统计学差异(P>0.05);两组治疗均有效,无统计学差异(P>0.05);在治疗费用方面B组明显少于A组,存在统计学差异(P<0.05)。结论:红霉素和阿奇霉素均可作为治疗儿童重症肺炎支原体肺炎的首选药物,但应用红霉素可减少联合用抗生素的时间及降低治疗费用。
Objective: To investigate the clinical efficacy of children with severe Mycoplasma pneumoniae pneumonia in order to improve the level of clinical diagnosis and treatment. Methods: Totally 77 children were divided into azithromycin group (A group) and erythromycin group (B group) according to the treatment of azithromycin and erythromycin. The clinical efficacy was observed. Results: There was no significant difference between the two groups in terms of gender, age, fever and pulmonary complications (P> 0.05). The time of combined antibiotics in group B was significantly shorter than that in group A (P <0.05), while the duration of antipyretic fever in group B was shorter than that in group A, and the number of pulmonary rales decreased in group A was shorter than that in group B and there was no significant difference in cough improvement days (P> 0.05) The treatment was effective, no statistical difference (P> 0.05). There was a statistically significant difference in treatment cost between group B and group A (P <0.05). Conclusion: Both erythromycin and azithromycin can be used as the drug of choice in treating children with severe mycoplasma pneumoniae pneumonia. However, the application of erythromycin can reduce the time of combination antibiotics and reduce the cost of treatment.